Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak | Zendy

Zachary A. Bornholdt | Zendy; Hannah L. Turner | Zendy; Charles D. Murin | Zendy; Wen Li | Zendy; Devin Sok | Zendy; Colby Souders | Zendy; Ashley E. Piper | Zendy; Arthur J. Goff | Zendy; Joshua D. Shamblin | Zendy; Suzanne E. Wollen-Roberts | Zendy; Thomas R. Sprague | Zendy; Marnie L. Fusco | Zendy; Kathleen B. J. Pommert | Zendy; Lisa A. Cavacini | Zendy; Heidi L. Smith | Zendy; Mark S. Klempner | Zendy; Keith A. Reimann | Zendy; Eric Krauland | Zendy; Tillman U. Gerngross | Zendy; K. Dane Wittrup | Zendy; Erica Ollmann Saphire | Zendy; Dennis R. Burton | Zendy; Pamela J. Glass | Zendy; Andrew B. Ward | Zendy; Laura M. Walker | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak

Author(s) -

Zachary A. Bornholdt,

Hannah L. Turner,

Charles D. Murin,

Wen Li,

Devin Sok,

Colby Souders,

Ashley E. Piper,

Arthur J. Goff,

Joshua D. Shamblin,

Suzanne E. Wollen-Roberts,

Thomas R. Sprague,

Marnie L. Fusco,

Kathleen B. J. Pommert,

Lisa A. Cavacini,

Heidi L. Smith,

Mark S. Klempner,

Keith A. Reimann,

Eric Krauland,

Tillman U. Gerngross,

K. Dane Wittrup,

Erica Ollmann Saphire,

Dennis R. Burton,

Pamela J. Glass,

Andrew B. Ward,

Laura M. Walker

Publication year - 2016

Publication title -

science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 12.556

H-Index - 1186

eISSN - 1095-9203

pISSN - 0036-8075

DOI - 10.1126/science.aad5788

Subject(s) - ebola virus , virology , outbreak , monoclonal antibody , antibody , ebolavirus , virus , isolation (microbiology) , neutralizing antibody , biology , medicine , immunology , microbiology and biotechnology

Antibodies targeting the Ebola virus surface glycoprotein (EBOV GP) are implicated in protection against lethal disease, but the characteristics of the human antibody response to EBOV GP remain poorly understood. We isolated and characterized 349 GP-specific monoclonal antibodies (mAbs) from the peripheral B cells of a convalescent donor who survived the 2014 EBOV Zaire outbreak. Remarkably, 77% of the mAbs neutralize live EBOV, and several mAbs exhibit unprecedented potency. Structures of selected mAbs in complex with GP reveal a site of vulnerability located in the GP stalk region proximal to the viral membrane. Neutralizing antibodies targeting this site show potent therapeutic efficacy against lethal EBOV challenge in mice. The results provide a framework for the design of new EBOV vaccine candidates and immunotherapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research